IL2 and diabetes mellitus: In order to assess whether Ab/IL-2 immunotherapy still expanded Tregs in NOD mice with established diabetes, we analyzed spleen, pancreatic lymph node, and pancreatic lymphocytes by flow cytometry (Figure 3d).